Adlai To Enter Clinical Trial Collaborations With Lilly, Merck KGaA To Explore Cetuximab With AN4035

Adlai Nortye (ANL) has partnered with Lilly (LLY) and Merck KGaA (MRCG.DE, MRK.DE) to explore cetuximab in trials with AN4035. Lilly and Merck will supply cetuximab for U.S., Australia, and China sites. ANL shares closed at $10.88 on Nasdaq.

Original reporting
Published Oct 15, 2026, 11:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ANL
Bullish
high confidence
Mentioned
$ANL · $MRK
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ANLBullishHigh
01

Why it matters

The collaboration is a fresh, material development for ANL, likely to move the stock higher on news flow.

02

Market read

New trial partnership provides a catalyst for ANL; limited direct impact on Lilly and Merck beyond supply role.

03

What to watch

The supply agreements are at no cost, but the trial's success depends on ANL's pan‑RAS ADC technology, which remains unproven.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Adlai Nortye Group (ANL) is a Nasdaq‑listed biotech developing a pan‑RAS inhibitor ADC (AN4035). The company secured free cetuximab supply from Lilly for US sites and Merck KGaA for Australia and China sites.

Company-level read

Ticker impact

$ANLBullishHigh confidence
Context

Adlai Nortye Group announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA for the anti‑EGFR antibody cetuximab.

Expected impact

likely upward pressure as investors price in the partnership and potential future data readouts

Evidence & confidence

The agreement provides free cetuximab supply for trials, reducing cost and de‑risking the program, a material catalyst for a micro‑cap biotech.

Market effects

Adds to the pipeline activity in the anti‑EGFR and ADC space, potentially benefiting peers with similar targets.

US biotech market may see modest uplift; European partners (Merck KGaA) gain visibility.

Limited to biotech investors, but could attract interest from larger pharma partners.

Counterpoint

If the trial fails to show efficacy, the partnership could be a sunk cost and the stock may face downside.

Key entities

  • Adlai Nortye Group

    Nasdaq‑listed biotech developing AN4035.

  • Eli Lilly

    Supplier of cetuximab for US trial sites.

  • Merck KGaA

    Supplier of cetuximab for Australia and China trial sites.

Related articles

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$MRKMed

Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns

Merck (MRK) is discontinuing development of nemtabrutinib, an experimental BTK inhibitor acquired via its $2.7B purchase of ArQule, due to safety concerns identified in late-stage trials. The decision follows recommendations from a data monitoring committee and Merck's own review, leading to the halt of several Phase 3 studies in the BELLWAVE program. The drug was being evaluated for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

$MRKLow

Merck names Douglas Baker as independent lead director

Merck & Co. (NYSE: MRK) announced Douglas M. Baker, Jr. will become independent lead director of its board, effective January 1, 2027. Baker, who has served on the board since 2022, will succeed Thomas H. Glocer. Merck's CEO Rob Davis praised Baker's leadership experience. The announcement was made on Wednesday.

$MRKMed

MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib

MSD (Merck & Co) halted its Phase III BELLWAVE-011 trial of nemtabrutinib for leukaemia after an external review found potential risks outweighed benefits. The company also terminated the wider BELLWAVE program, including two other Phase III trials. MSD plans to share full findings and continue developing treatments for blood cancers. According to GlobalData, CLL/SLL cases in major markets are expected to rise to 478,279 by 2032.